Videos

BOND-003 Cohort P Trial TT

Search

BOND-003 Trial Results in BCG Unresponsive Non-muscle Invasive Bladder Cancer - Mark Tyson Details Zachary Klaassen hosts Mark Tyson to discuss the BOND-003 trial evaluating cretostimogene for BCG-unresponsive NMIBC. This study examines the mechanism by which this oncolytic immunotherapy selectively targets cancer cells by exploiting Rb pathway deficiencies and enhancing tumor-specific immunity through GM-CSF expression. The discussion highlights the treatment's promising efficacy with high com...
BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC - Mark Tyson Details Sam Chang speaks with Mark Tyson about the BOND-003 trial's findings on cretostimogene grenadenorepvec for treating BCG unresponsive carcinoma in situ of the bladder. Dr. Tyson explains the dual-action mechanism of the drug, combining direct tumor cell destruction with enhanced immune response activation. Impressively, the trial shows a 75.2% complete response rate at various time points with a ti...
Breaking Paradigms: BOND-003's Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mark Tyson Details Mark Tyson presents results from the BOND-003 study, evaluating the efficacy of cretostimogene grenadenorepvec monotherapy in treating BCG-unresponsive non-muscle-invasive bladder cancer. Cretostimogene, an oncolytic adenovirus, selectively targets and destroys cancer cells while sparing normal tissue and boosting antitumor immunity. The phase III study reported a 75.2% complete response rate, wit...